Skip to main content

Day: September 11, 2025

Guidance for the 2025/26 financial year

ANNOUNCEMENT NO. 291 11 September 2025Guidance for the 2025/26 financial year  ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For 2025/26, ChemoMetec expects revenue in the range of DKK 545-565 million (2024/25: DKK 495.6 million) and EBITDA in the range of DKK 295-315 million (2024/25: DKK 258.0 million). The annual report for 2024/25, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidance for 2025/26 (p. 39-40).Additional information Martin Helbo Behrens, CEOTel.: (+45) 48 13 10 20 Kim Nicolajsen, CFOTel.: (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments...

Continue reading

Vranken-Pommery Monopole : Financial Press Release First-Half 2025 Results

FINANCIAL PRESS RELEASE FIRST-HALF 2025 RESULTS A performance that translates into a slight improvement in net incomeConsolidated revenue stable at €109.3m (-0.2%) +€0.5m increase in Group net incomeReims, September 11, 2025The Board of Directors of Vranken-Pommery Monopole met on September 11, 2025 under the chairmanship of Mrs. Nathalie Vranken, and in the presence of the Statutory Auditors, to approve the Group’s financial statements for the half year 2025.The limited review procedures on the half-year financial statements have been performed by the Statutory Auditors, their report is being issued.Consolidated dataH1 2025 (€m) H1 2024 (€m) Var vs H1 24 (€m) Var vs H1 24 (%)Turnover 109.3 109.6 -0.2 -0.2%Recurring operating income 13.8 15.1 -1.2 -8.0%Operating income 13.7 14.7 -1.1 -7.2%Financial result -15.3 -16.4 +1.0  ...

Continue reading

ASUS Listed on TIME’s World’s Best Companies 2025 for the Second Time

The esteemed ranking celebrates ASUS for outstanding performance in employee satisfaction, revenue growth, and sustainable practices KEY POINTSTIME recognition: ASUS secures its second inclusion on TIME’s World’s Best Companies that set the standard in innovation, growth, employee satisfaction A commitment to innovation: ASUS validated for its leadership in fostering a great workplace, driving business growth, and advancing sustainability Global distinction: ASUS continues to receive worldwide acclaim from esteemed organizations like Fortune, Forbes, and NewsweekTORONTO, Sept. 11, 2025 (GLOBE NEWSWIRE) — ASUS today announced its second appearance in TIME magazine’s prestigious list of the World’s Best Companies. This accolade recognizes organizations that set the standard in employee satisfaction, revenue growth, and sustainability...

Continue reading

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025

Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers) Paris, France (September 11, 2025 – 6:00 pm) – As of August 31, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below.  August 31, 2025Shares outstanding 463,145,529Number of real voting rights (excluding treasury shares) 461,157,737Theoretical number of voting rights (including treasury shares) 463,145,529It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula contained in article...

Continue reading

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell CancerA total of 105 HLA-A2 positive patients enrolled in the Combi-TED study, which explores the combination of Tedopi® with either an anti-PD1 checkpoint inhibitor or chemotherapy as a second-line treatment for metastatic Non-Small Cell Lung Cancer following first-line chemo-immunotherapy. Top-line results expected in the second half of 2026.NANTES, France – ROME, Italy – September 11, 2025, 6:00 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotechnology company focused on developing first-in-class therapies in immuno-oncology and immuno-inflammation, and the FoRT Foundation (Fondazione...

Continue reading

Hermès International : Shares and voting rights as of 31st August 2025

RELEASE Paris, September 11, 2025 INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES COMPRISING THE SHARE CAPITALIn accordance with the provisions of Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF), Hermès international publishes each month, before the 15th day of the following month, the total number of voting rights and the number of shares comprising the share capital if they have varied from those previously published.Date Total number of shares Total number of theoretical voting rights (including treasury stock) Total number of effective voting rights (exercisable at shareholders’ meetings) Publications31 August 2025 105 569 412 179 545 613 178 811 721 11 September 202531 July 2025 105 569 412 179 550 181 178 816 459 11...

Continue reading

Ipsen – August 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11Date Total number of shares composing the share capital Total number of voting rights (1)31 August 2025 83,814,526 Gross total* of voting rights: 132,062,873Net total** of voting rights: 130,937,383(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10). * Gross total = total number of voting rights attached to the total number of shares, including the number of shares...

Continue reading

FORVIA FURTHER IMPROVES ITS DEBT PROFILE BY USING THE €600M PROCEEDS FROM ITS NEW SENIOR NOTES DUE 2031 AND AVAILABLE CASH TO REPURCHASE €700M OF BONDS MATURING IN 2027

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1993, AS AMENDED (THE “SECURITIES ACT”)) OR ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE US VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. NANTERRE (FRANCE)SEPTEMBER 11, 2025 FORVIA FURTHER IMPROVES ITS DEBT PROFILE BY USING THE €600M PROCEEDS FROM ITS NEW SENIOR NOTES DUE 2031 AND AVAILABLE CASH TO REPURCHASE €700M OF BONDS MATURING IN 2027 With the success of the cash tender offers for the repurchase of FORVIA’s...

Continue reading

PETROBRAS CHOOSES VALLOUREC TO SUPPORT $1BN OFFSHORE OCTG PROJECTS

PETROBRAS CHOOSES VALLOUREC TO SUPPORT $1BN OFFSHORE OCTG PROJECTS Meudon (France), on September 11, 2025 – Vallourec, a world leader in premium seamless tubular solutions, has been awarded a major contract by Petrobras as a result of a competitive bidding process for the supply of OCTG (Oil Country Tubular Goods) products and services for its offshore operations from 2026 to 2029. This long-term agreement could generate total revenue of up to USD 1 billion, representing the widest award both in volumes and revenues since Petrobras adopted the open tender strategy. This contract covers the full OCTG scope of supply for seamless pipes and VAM® premium connections required for Petrobras’ offshore wells from 4.5” up to 18”, including carbon and stainless-steel tubulars and associated accessories. Vallourec will also deliver comprehensive...

Continue reading

Information relating to the total number of voting rights and share capital – August 31, 2025

Disclosure of the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the French Commercial Code and the Article 223-16 of the Règlement général de l’Autorité des marchés financiers   (Regulation of the French stock market authority) Company name of the issuer:         Renault S.A. 122 – 122 bis Avenue du Général Leclerc 92100 Boulogne-Billancourt (ISIN code: FR0000131906 – RNO)Date Total number of issued shares Total number of voting rightsAugust 31, 2025295,722,284Theoretical number of voting rights (1): 403,545,398Exercisable number of voting rights (2): 397,701,889(1)   Pursuant to Article 223-11 of the Règlement général de l’Autorité des marchés financiers, number calculated on the basis of all shares to which voting rights are attached, including shares for which voting...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.